Binghua W. Li - Publications

Fatty Acid Degradation (FAD) Subtype-Informed Treatment Allocation in Unresectable Hepatocellular Carcinoma (FAD-HCC-01): Protocol for a Prospective Multicentre Proof-of-Concept Study.

Journal: Journal of hepatocellular carcinoma

Published: March 11, 2026

Heterogeneity of hepatic macrophages in MASLD/MASH: Lipid-associated programs, molecular mechanisms, spatial niches, and therapeutic implications.

Journal: iLIVER

Published: January 04, 2026

Histone delactylation shapes epigenetic landscapes and therapeutic stratification in hepatocellular carcinoma.

Journal: iLIVER

Published: December 09, 2025

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD-1 Inhibitors in Advanced Hepatocellular Carcinoma.

Journal: Cancer medicine

Published: November 11, 2025

Improved risk stratification in patients with colorectal liver metastases by incorporating volumetric body composition analysis.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: October 24, 2025

Non-contrast magnetic resonance imaging outperforms contrast-enhanced computed tomography in preoperative detection of hepatocellular carcinoma: A paired validation study.

Journal: Clinical and molecular hepatology

Published: August 18, 2025

Letter to the Editor: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: July 19, 2025

Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.

Journal: Hepatology (Baltimore, Md.)

Published: May 26, 2025

Molecular stratification of hepatocellular carcinoma by metabolic-signaling pathways guides precision immunotherapy and TACE therapy.

Journal: Clinical and molecular hepatology

Published: March 27, 2025

PLAGL2 promotes HCC progression by recruiting tumour-associated macrophages via CCL2/CCR2 signalling.

Journal: British journal of pharmacology

Published: March 21, 2025

β-catenin mutation reprograms ketone body metabolism to drive hepatocellular carcinoma metastasis and resistance to ketogenic therapy via transcriptional activation of OXCT1.

Journal: Cell death & disease

Published: March 20, 2025

S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: January 16, 2025